In the past, Emma Cullen required twice-yearly intravenous (IV) infusions, requiring up to four hours every visit.
The drug ocrelizumab slows the course of Multiple Sclerosis (MS) and helps to prevent relapses.
The administration of the medication by subcutaneous injection has received approval.
The NHS states that multiple sclerosis (MS) is a disorder that affects the brain and spinal cord.
Although there isn’t a solution at this time, there are treatments available to assist control symptoms.
Instead of attacking and killing viruses and bacteria, the immune system’s particular cells target and destroy nerves in people with multiple sclerosis.
The MS Society states that ocrelizumab focuses on B cells, one subset of these cells, and prevents them from entering the brain and spinal cord.
The first injection in the United Kingdom was given at Morriston Hospital by the Swansea Bay University Health Board, which participated in the drug’s clinical trial.
Patients with either early primary progressive MS, in which symptoms gradually deteriorate, or active relapsing MS, in which symptoms can disappear or improve following a flare-up, are treated with this medication.
